$Axcelis Technologies (ACLS.US)$In the March 2022 analysis, ...

Launched in 2000, it mainly deals in the ion implantation and plasma etching equipment business. 66.3% of the market is in the US, and the current price is 111.92.

In the past 5 years, revenue has increased for 4 years, with an average growth rate of 20.6%, an average growth rate of 34.5% in operating profit, and an average growth rate of 40% in net profit. Interest expenses will be converted to interest income in 2023, and there is no interest burden. Gross margin has basically fluctuated around 42% in the past 5 years, and the return on net assets has gradually increased from 4% to 32.2%.

The balance ratio has increased from 23.5% to 32.5 over the past 5 years. The ratio and growth rate of accounts receivable are normal, and inventory is growing slightly faster. Currently, it accounts for 27% of 2023 revenue, which is slightly higher. There are no interest-bearing loans.

It currently has 506 million dollars in cash, a current ratio of 3.8, and a quick ratio of 2.5.

Net cash flow from operating over the past 5 years has been higher than net investment, generating a large number of shareholders' surpluses.

The current price-earnings ratio is 15.1. Considering being in a cyclical sector, you can choose carefully (⭐️)